Abstract. Numerous st udies have repor ted that microRNA (miR)-
Introduction
Lung cancer is a multistep process involving alterations in the expression of oncogenes and tumor suppressor genes via numerous factors, including alcohol, smoking, pathogenic infections and genetic factors (1-3). Lung cancer is the most frequently diagnosed cancer and its incidence has been increasing in recent years (2, 3) . It remains a leading cause of cancer-associated mortality worldwide for men and women (4, 5) , but the pathogenesis of this disease remains unknown (6) .
PDZ-binding-kinase/T-LAK cell-originated protein kinase (PBK/TOPK) is a 322-amino acid serine/threonine kinase (7) . In normal tissues, is difficult to detect PBK/TOPK protein, other than in the germ cells of the testis and numerous fetal tissues (8) . The overexpression of PBK/TOPK has been observed in activated T-LAK cells, which interacted with fruit plate-large human homologues via the C-terminal PDZ binding motif of TOPK (9) . PBK/TOPK is widely expressed in a variety of malignancies, including leukemia, lymphoma and breast cancer, and malignant peripheral nerve sheath tumors (10) (11) (12) . PBK/TOPK overexpression contributes to tumor proliferation and growth in Ewing sarcoma, colorectal cancer and breast cancer (13, 14) . In lung cancer, patients exhibit poor clinical outcome with high expression of PBK/TOPK (15) . Recently, PBK/TOPK overexpression was reported to be closely associated with tumor malignancy potential and poor outcome of patients with gastric cancer (16) . In addition, high expression of PBK/TOPK may serve as a favorable prognostic marker for (17) . In molecular studies, PBK/TOPK expression was associated with cell mitotic regulation, inflammation and apoptosis (18) . MicroRNAs (miRNAs/miRs) are non-coding RNAs that inhibit gene expression by inhibiting the translation of target mRNAs or by degrading them. miRNAs have been demonstrated to interact directly with the 3'-untranslated region (3'-UTR) of target mRNAs (19) . miRNAs regulate numerous cell functions, including proliferation, differentiation, metastasis and apoptosis (19) . Studies have indicated that altered miRNA expression levels are associated with cancer (20, 21) . miRNAs may serve as oncogenes or tumor suppressors, depending on the organs and tumors in which they are expressed (22) (23) (24) . miR-216b has been studied in a variety of cancer types. For instance, miR-216b was reported to be closely associated with the prognosis of cervical cancer patients and may inhibit cervical cancer cell proliferation via regulating forkhead box protein M1 (FOXM1) expression (25) . miR-216b prevented the migration and invasion of glioma cells by suppressing FOXM1 expression (26) . Liu et al (27) reported that miR-216b was involved in cisplatin resistance in ovarian cancer by the regulation of poly adenosine 5'-diphosphate-ribose polymerase 1. Furthermore, miR-216b may inhibit hepatocellular carcinoma cell proliferation, migration and invasion by regulating insulin-like growth factor 2 mRNA-binding protein 2 (28) . However, the role and mechanism of miR-216b-3p in lung adenocarcinoma requires further investigation.
MicroRNA-216b-3p inhibits lung adenocarcinoma cell growth via regulating PDZ binding kinase/T-LAK-cell-originated protein kinase
The present study aimed to explore the effects of miR-216b-3p on lung adenocarcinoma, and the association between miR-216b-3p and PBK/TOPK. Herein, the molecular functions and underlying mechanism of miR-216b-3p were investigated. Cell culture. A549, GLC-82, H358 and BEAS-2B cells were cultured in DMEM containing 10% FBS, 100 U/ml penicillin and 100 U/ml streptomycin (pH 7.2) in a 5% CO 2 atmosphere at 37˚C.
Materials and methods

Reagents
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. Total RNA was isolated from A549, GLC-82, H358 and BEAS-2B cells using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The first strand cDNA synthesis was performed with 1 µg RNA in the reaction mixture of 10 µl with 50 pmol random hexamers and 50 units of M-MLV RTase. Conditions were as following: 16˚C for 30 min, 42˚C for 30 min, 85˚C for 5 min, and hold at 4˚C. Subsequently, qPCR was performed to analyze the synthesized cDNA using the QuantiTect SYBR Green PCR kit (Qiagen GmbH, Hilden, Germany). The master mix (20 µl) contained 2 µl 10x reverse transcription buffer, 1 µl deoxynucleotides (100 mM; with thymidine triphosphate), 0.25 µl 2 µM forward primer, 0.25 µl 2 µM reverse primer, 5 µl 1 ng/µl cDNA and 11.5 µl nuclease-free water. The amplification conditions were as follows: 38 cycles of denaturation at 95˚C for 10 sec, followed by 60˚C for 60 sec to allow annealing and extension. U6 and GAPDH served as the internal controls for miR-216b-3p and PBK expression respectively. qPCR was conducted with the following primers: miR-216b-3p forward, 5'-CAG GCA CAC ACT TAC CCG TA-3' and reverse, 5'-GCA GGG TCC GAG GTA TTC-3'; U6 forward, 5'-CTC GCT TCG GCA GCA CAT ATA CT-3' and reverse, 5'-ACG CTT CAC GAA TTT GCG TGT C-3'; GAPDH forward, 5'-GAA GGT GAA GGT CGG AGT C-3' and reverse, 5'-GAA GAT GGT GAT GGG ATT TC-3'; and PBK forward, 5'-CCA AAC ATT GTT GGT TAT CGT GC-3' and reverse, 5'-GGC TGG CTT TAT ATC GTT CTT CT-3'. Relative gene expression was calculated by using the 2 -ΔΔCq method (29) . The test was performed three times in triplicate.
Western blot analysis. Harvested A549, GLC-82, H358 and BEAS-2B cells were briefly washed with cold PBS. On ice, they were lysed in radioimmunoprecipitation complete lysis buffer [50 mM Tris, pH 7.2; 1% sodium deoxycholate; 150 mM NaCl; 0.1% SDS; 10 mM NaF; 1% Triton-X 100; 1 mM Na3VO4; protease inhibitor cocktail (1:800)]. Lysates were sonicated 3 times at 4˚C, each time 10 sec (frequency, 20 kHz) and centrifuged at 13,000 x g for 10 min at 4˚C. Serum albumin was used as the standard and protein concentration was determined with bicinchoninic acid as previously described (30) . Total protein (30 µg/lane) was separated using 12% SDS-PAGE and transferred to polyvinylidene difluoride membranes. Subsequently, membranes were incubated with PBS containing 0.05% Tween-20 and 5% non-fat dry milk at room temperature for 1.5 h to block non-specific binding and were incubated with PBK/TOPK (cat no. 4942), p53 (Cat no. 2527), p21 (cat no. 2947), p-p38 (cat no. 4511) and β-actin (cat no. 4970) primary antibodies (all 1:1,000; Cell Signaling Technology, Danvers, MA, USA), then treated with anti-rabbit Immunoglobulin G horseradish peroxidase-coupled secondary antibody (cat no. 7074; 1:1,000; Cell Signaling Technology) as described (31) . Immunoreactive bands were observed with enhanced chemiluminescence using the SignalFire™ Plus ECL Reagent (cat no. 12630; Cell Signaling Technology) and imaged by ChemiDoc XRS+ System (Bio-Rad Laboratories). The band density was quantified with Gel-Pro Analyzer densitometry software (version 6.3; Media Cybernetics, Inc., Rockville, MD, USA).
Transient transfection. Cells were transiently transfected with 50 nM miR-216b-3p mimic (Pre-miR™ miR-216b-3p; sense, 5'-AAA UCU CUG CAG GCA AAU GUG A-3' and antisense, 5'-ACA UUU GCC UCC AGA GAU UUU U-3'; Thermo Fisher Scientific, Inc.), 50 nM negative control (negative control miRNA; sense, 5'-UUC UCC GAA CGU GUC ACG UTT-3' and antisense, ACG UGA CAC GUU CGG AGA ATT-3'; Thermo Fisher Scientific, Inc.), 2 µg control plasmids, 2 µg PBK/TOPK plasmids (PBK CRISPR/Cas9 KO Plasmid (h); cat no. sc-404069; Santa Cruz Biotechnology, Inc., Dallas, CA, USA) or 50 nM miR-216b-3p mimic + 2 µg PBK/TOPK plasmids using Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. Cells were seeded at a density of 5x10 4 cells per well in a 6-well plate. At 48 h post-transfection, the cells were subjected to subsequent analysis.
Luciferase reporter assay. Bioinformatics software (targetscan.org/vert_71) was used to predict the targets of miR-216b-3p; PBK was identified as a potential target of miR-216b-3p. To determine whether miR-216b-3p directly targets the 3'-UTR of PBK, the psiCHECK-2 reporter plasmid (Sangon Biotech Co., Ltd., Shanghai, China) vectors named PBK-3'UTR-WT and PBK-3'UTR-MUT with wild type and mutated 3'UTR of PBK mRNA, respectively, were constructed as previously described (32) . GLC-82 cells (5x10 4 cells/well) were seeded in a 24-well plate and then co-transfected with PBK-3'UTR-WT or PBK-3'UTR-MUT and miR-216b-3p or its negative control (miR-NC) vector using Lipofectamine ® 2000 transfection reagent according to the manufacturer's protocols. A total of 48 h after transfection, the luciferase activity was detected using the Dual-Luciferase Reporter Assay kit (Promega Corporation, Madison, WI, USA) according to the manufacturer's protocol and normalized to Renilla luciferase activity.
Flow cytometry for apoptosis analysis. For apoptosis analysis, 1x10
5 cells/well were seeded in 6-well plates and incubated in DMEM containing 10% FBS at 37˚C for 48 h. After 48 h, the harvested floating and adherent cells were washed twice with cold PBS. Cells were stained with Annexin V-fluorescein isothiocyanate and propidium iodide (cat. no. 6592; Cell Signaling Technology) in 500 µl binding buffer at room temperature for 15 min, and then analyzed with a BD FACSCelesta™ flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) using WinMDI (Version 2.5; Purdue University Cytometry Laboratories, West Lafayette, IN, USA) within 1 h (28).
Cell proliferation assay. Cell proliferation was examined by a MTT assay. A total of 48 h after transfection, GLC-82 cells (4x10 3 cells/well) were seeded into 96-well culture plates and incubated in 5% CO 2 at 37˚C. Then, 20 µl MTT (5 mg/ml) was added to each well and the cells were incubated for another 4 h at 37˚C. Following removal of MTT, 100 µl dimethyl sulfoxide was added to each well, and the plate was gently agitated for 10 min at room temperature. The absorbance was measured with a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA) at 490 nm. All experiments were repeated ≥3 times (33) .
Statistical analysis. Experiments were performed for at least three times. Data are expressed as the mean ± standard deviation. SPSS 17.0 statistical software (SPSS, Inc., Chicago, IL, United States) was performed for all statistical analyses. Statistical analysis was performed using a Student's t-test or one-way analysis of variance followed by Tukey's test where appropriate. P<0.05 was considered to indicate a statistically significant difference.
Results
Low expression of miR-216b-3p in lung adenocarcinoma cell lines.
The expression levels of miR-216b-3p in human lung adenocarcinoma cell lines (A549, GLC-82 and H358 cells) and human normal lung epithelial cell line BEAS-2B were analyzed. The results of the present study indicated that the expression levels of miR-216b-3p in all lung adenocarcinoma cell lines (A549, GLC-82 and H358 cells) were significantly lower compared with BEAS-2B cells. The lowest expression level of miR-216b-3p was in GLC-82 cells (Fig. 1) . Therefore, GLC-82 cells were selected for subsequent in vitro studies in the present study.
Overexpression of PBK/TOPK in lung adenocarcinoma cell lines.
Western blotting and RT-qPCR were performed to test whether PBK/TOPK was overexpressed in lung adenocarcinoma cell lines. PBK/TOPK was expressed at low levels within BEAS-2B cells. However, the protein and mRNA expression levels of PBK/TOPK were increased in all lung adenocarcinoma cell lines (A549, GLC-82 and H358 cells), compared with BEAS-2B cells, with the largest increase in GLC-82 (Fig. 2) . These results suggested that PBK/TOPK may be a target of activation in lung adenocarcinoma.
PBK is a direct target gene of miR-216b-3p.
The aforementioned results demonstrated that miR-216b-3p and PBK/TOPK expression may be dysregulated in lung adenocarcinoma cell lines. Therefore, miR-216b-3p and PBK/TOPK may have a direct association. TargetScan was employed to predict the target gene of miR-216b-3p (Fig. 3A) . PBK was identified as a direct target gene of miR-216b-3p and a double luciferase reporter assay revealed the same result (Fig. 3B) .
To investigate the function of miR-216b-3p in lung adenocarcinoma, synthesized miR-216b-3p mimics, miR-NC, control plasmids, PBK/TOPK plasmids or miR-216b-3p mimic + PBK/TOPK plasmids were transfected into GLC-82 cells (Fig. 3C-F) . At 48 h post-transfection, the transfection efficiency was determined by RT-qPCR ( Fig. 3C and F) . The results indicated that miR-216b-3p mimics significantly enhanced miR-216-3p expression in GLC-82 cells and PBK/TOPK plasmids significantly increased the mRNA level of PBK/TOPK. To further reveal whether miR-216b-3p may regulate PBK/TOPK in GLC-82 cells, at 48 h after GLC-82 cell transfection with miR-216b-3p mimics or miR-NC, the protein and mRNA expression levels of PBK/TOPK were detected by western blotting and RT-qPCR respectively. The results of the present study indicated that miR-216b-3p mimics may inhibit PBK/TOPK expression in GLC-82 cells ( Fig. 3D  and E) . Collectively, the data suggested that PBK may be a direct target gene of miR-216b-3p and may be negatively regulated by miR-216b-3p.
miR-216b-3p overexpression inhibits GLC-82 cell proliferation and induces cell apoptosis via regulating
PBK/TOPK expression. Cells were transiently transfected with miR-216b-3p mimics, miR-NC or miR-216b-3p mimics + PBK/TOPK plasmids. An MTT assay was conducted to detect the proliferation of GLC-82 cells; flow cytometry was used to analyze apoptosis. The results demonstrated that miR-216b-3p overexpression significantly inhibits GLC-82 cell proliferation (Fig. 4) and induces cell apoptosis (Fig. 5 ) compared with the control. These effects were eliminated by PBK/TOPK overexpression (Figs. 4 and 5) .
miR-216b-3p overexpression affects p53, p21 and phosphorylated (p) -p38 expression.
To further investigate the molecular mechanism of miR-216b-3p, the expression of p53, p21 and p-p38 was detected by western blot analysis. The results demonstrated that the overexpression of miR-216b-3p increased the expression of p53 and p21, and decreased the expression of p-p38. These effects also appeared to be eliminated by PBK/TOPK overexpression (Fig. 6 ).
Discussion
According a previous report, miRNAs serve a regulatory role in cell growth, proliferation, apoptosis, differentiation, migration and metabolism (34) . In the present study, the expression of miR-216b-3p was detected in a variety of lung adenocarcinoma cell lines and the results demonstrated that within all lung adenocarcinoma cell lines (A549, GLC-82 and H358 cells), miR-216b-3p expression levels was significantly lower compared with BEAS-2B cells. This indicated that miR-216b-3p was associated with lung adenocarcinoma. GLC-82 cells, which expressed the lowest level of miR-216b-3b, were selected for further analysis.
PBK/TOPK gene expression is increased in various types of cancer, including bladder cancer, brain tumors, breast Figure 6 . Effects of miR-216b-3p on the expression of p53, p21 and p-p38 in GLC-82 cells. After 48 h post-transfection, western blotting was performed to determine the effect of miR-216b-3p the expression of p53, p21 and p-p38 in GLC-82 cells. Control, control group, cells without any treatment; NC, negative control group, cells transfected with the negative control vector of miR-216b-3p mimics; mimic, cells transfected with miR-216b-3p mimics; mimic + plasmid, cells co-transfected with miR-216b-3p mimics and PDZ-binding-kinase/T-LAK cell-originated protein kinase plasmids. miR, microRNA; p-, phosphorylated. cancer, liver cancer, lung cancer and sarcoma (35, 36) . In the present study, the expression levels of PBK/TOPK were observed to be significantly increased within lung adenocarcinoma cells. These results suggested that the expression of miR-216b-3p and PBK/TOPK was dysregulated in lung cancer. Therefore, miR-216b-3p may be involved in tumor development by regulating PBK/TOPK expression. TargetScan was used to predict the target gene of miR-216b-3p, which suggested that miR-216b-3p was targeted to PBK and a double luciferase reporter gene system validated this result. Furthermore, the overexpression of miR-216b-3p in GLC-82 cells significantly inhibited cell proliferation and induced cell apoptosis; when co-transfected with PBK/TOPK, the inhibitory effect exerted by miR-216b-3p was reversed. These results indicated that miR-216b-3p may be considered to be a tumor suppressor by decreasing the expression of PBK/TOPK.
As a member of the mitogen-activated protein kinase kinase family, PBK/TOPK protein is highly expressed in various types of cancer. p53 is considered to be one of the most common tumor suppressors; wild type p53 is involved in apoptosis, cell-cycle arrest and DNA repair (37) . The loss of p53 function caused by mutations, however, is associated with the majority of human cancers (38) . Mutant p53 is able to not only promote invasion, migration and proliferation, but also enhance genomic instability and chemoresistance (39) . It was reported that a p53 mutation is closely associated with the occurrence and progression of lung cancer (40) . Additionally, Hu et al (7) revealed that PBK/TOPK may inhibit p53 function and promote the development and progression of tumor cells. The expression levels of p53, p21 and p-p38 were also determined in the present study, and the data demonstrated that the overexpression of miR-216b-3p may inhibit PBK/TOPK. Thus, increases in p53 and p21, and decreases in p-p38 expression, may exert an antitumor effect.
In summary, the present study provided novel evidence that decreased miR-216b-3p expression may contribute to lung adenocarcinoma development by increasing the expression of PBK/TOPK. Furthermore, PBK/TOPK expression may be beneficial to the promotion of cell proliferation and viability. Therefore, miR-216b-3p and PBK/TOPK may be considered as potential clinical indicators and therapeutic targets for the treatment of lung adenocarcinoma.
